Sunshine Biopharma Inc. (SBFMW) bonds

SBFMWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SBFM

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30

$0.03+0.00 (+2.00%)

Close on Oct 30, 2026Market cap $11.36MP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Individual notes, bonds and loans

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.

Parsed from the XBRL in Sunshine Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Jun 1, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SBFMW.

Revenue growth-2.7% · median 135.5%

Gross margin30.3% · median 83.8%

Operating margin-16.6% · median -131.4%

Net margin-16.5% · median -348.0%

Advertisement
300 × 250